HEPA: Hepion Pharma Company Aggregate Debts

Hepion Pharmaceuticals (HEPA) bases its business on combating fibrosis and liver obesity, relying on insurance fund payouts. However, the failure of interim tests for its lead drug triggered sharp spending cuts and the closure of centers. Stability is maintained by optimized biomass flows and a network of laboratories, where the indicator is 0.00. The asset's valuation dynamics on the GURU.Markets platform clearly demonstrate the company's current financial condition.

HEPA: Hepion Pharmaceuticals Inc. Company Debts 07/04/2022 - 06/14/2025

Hepion Pharmaceuticals (HEPA) - metric breakdowns and financial figures

- share price and consensus valuation forecast:

Price Performance Chart hepionpharma.com|HEPA - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization Hepion Pharma|HEPA - Total Company Value

- balance sheet equity data:

Accounting Value of a Share Hepion Pharmaceuticals|HEPA - Company Book Value|Market Cap to Net Assets Ratio hepionpharma.com|HEPA - Company Total Assets

- issuer credit burden and liquidity indicators:

- earnings and valuation multiples information:

HEPA - Net Profit

Fundamental company analysis:Hepion Pharmaceuticals Inc. HEPA

Signature product of Hepion Pharmaceuticals, Inc.

The development of steatohepatitis therapy and the success of the drug CRV431 require significant funding, making the borrowing structure a critical factor for the sustainability of Hepion Pharmaceuticals (HEPA). This metric aggregates the total volume of external debt capital, allowing for an assessment of the company's ability to service its debts and fund R&D without the risk of default or share dilution through changes in total liabilities.

Competing companies